All In Biotech

NDA 214377 · Msd

Verquvo

Vericiguat · Oral · Soluble Guanylate Cyclase Stimulator

NovelPriority review

CDER novel approval, Jan 19, 2021: To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure

Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jan 19, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

37

3 Phase 3, 11 recruiting

FAERS reports

994

510 serious, 152 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.3) ] . WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Do not administer VERQUVO to a pregnant female because it may cause fetal harm. ( 4 , 5.1 , 8.1 ) Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment....

What it is approved for

From the label in effect Jan 21, 2026.

VERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ] . VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%. ( 1 )

Mechanism: Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, vericiguat...

Therapeutic areas: Cardiovascular and metabolic · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 21, 2026 Supplement 5 · Efficacy LabelLetter
  • Jan 19, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
  • VERQUVO · VERICIGUAT 5MG · TABLET, ORAL · Prescription
  • VERQUVO · VERICIGUAT 10MG · TABLET, ORAL · Prescription
  • VERQUVO · VERICIGUAT 2.5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vericiguat" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension116
  • death98
  • cardiac failure77
  • dizziness69
  • product dose omission issue55
  • no adverse event49
  • blood pressure decreased43
  • anaemia40
  • fatigue37
  • dyspnoea36
  • malaise34
  • nausea31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20172
20183
2021114
2022218
2023213
2024177
2025181
202686

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Verquvo (Vericiguat)

2024 spending

$49.7M

Beneficiaries

11,127

49,590 claims

Per beneficiary

$4,465

$21.88 per unit

View as table
YearSpending
2020$0
2021$3,048,794
2022$15,714,170
2023$34,422,269
2024$49,680,167

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 74 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.